Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) FCF Margin (2017 - 2025)

Historic FCF Margin for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to 42.98%.

  • Protagonist Therapeutics' FCF Margin rose 5695000.0% to 42.98% in Q3 2025 from the same period last year, while for Sep 2025 it was 31.3%, marking a year-over-year decrease of 417500.0%. This contributed to the annual value of 42.08% for FY2024, which is 1601500.0% up from last year.
  • Per Protagonist Therapeutics' latest filing, its FCF Margin stood at 42.98% for Q3 2025, which was up 5695000.0% from 533.59% recorded in Q2 2025.
  • Protagonist Therapeutics' 5-year FCF Margin high stood at 6445.62% for Q2 2024, and its period low was 1547.22% during Q2 2022.
  • Its 5-year average for FCF Margin is 123.33%, with a median of 147.5% in 2022.
  • Its FCF Margin has fluctuated over the past 5 years, first tumbled by -114105400bps in 2021, then surged by 5695000bps in 2025.
  • Protagonist Therapeutics' FCF Margin (Quarter) stood at 314.9% in 2021, then surged by 91bps to 28.18% in 2022, then skyrocketed by 220bps to 33.88% in 2023, then crashed by -153bps to 17.87% in 2024, then plummeted by -140bps to 42.98% in 2025.
  • Its FCF Margin stands at 42.98% for Q3 2025, versus 533.59% for Q2 2025 and 440.73% for Q1 2025.